Weideman, Ann MarieBarbour, ChristopherTapia-Maltos, Marco AurelioTran, TanJackson, KaylaKosa, PeterKomori, MikaWichman, AlisonJohnson, KoryGreenwood, Mark C.Bielekova, Bibiana2018-07-112018-07-112017-11Weidman, Ann Marie, Christopher Barbour, Marco Aurelio Tapia-Maltos, Tan Tran, Kayla Jackson, Peter Kosa, Mika Komori, Alison Wichman, Kory Johnson, Mark Greenwood, and Bibiana Bielekova. "New Multiple Sclerosis Disease Severity Scale Predicts Future Accumulation of Disability." Frontiers in Neurology 8 (November 2017). DOI:https://dx.doi.org/10.3389/fneur.2017.00598.1664-2295https://scholarworks.montana.edu/handle/1/14641The search for the genetic foundation of multiple sclerosis (MS) severity remains elusive. It is, in fact, controversial whether MS severity is a stable feature that predicts future disability progression. If MS severity is not stable, it is unlikely that genotype decisively determines disability progression. An alternative explanation tested here is that the apparent instability of MS severity is caused by inaccuracies of its current measurement. We applied statistical learning techniques to a 902 patient-years longitudinal cohort of MS patients, divided into training (n = 133) and validation (n = 68) sub-cohorts, to test four hypotheses: (1) there is intra-individual stability in the rate of accumulation of MS-related disability, which is also influenced by extrinsic factors. (2) Previous results from observational studies are negatively affected by the insensitive nature of the Expanded Disability Status Scale (EDSS). The EDSS-based MS Severity Score (MSSS) is further disadvantaged by the inability to reliably measure MS onset and, consequently, disease duration (DD). (3) Replacing EDSS with a sensitive scale, i.e., Combinatorial Weight-Adjusted Disability Score (CombiWISE), and substituting age for DD will significantly improve predictions of future accumulation of disability. (4) Adjusting measured disability for the efficacy of administered therapies and other relevant external features will further strengthen predictions of future MS course. The result is a MS disease severity scale (MS-DSS) derived by conceptual advancements of MSSS and a statistical learning method called gradient boosting machines (GBM). MS-DSS greatly outperforms MSSS and the recently developed Age Related MS Severity Score in predicting future disability progression. In an independent validation cohort, MS-DSS measured at the first clinic visit correlated significantly with subsequent therapy-adjusted progression slopes (r = 0.5448, p = 1.56e-06) measured by CombiWISE. To facilitate widespread use of MS-DSS, we developed a free, interactive web application that calculates all aspects of MS-DSS and its contributing scales from user-provided raw data. MS-DSS represents a much-needed tool for genotype-phenotype correlations, for identifying biological processes that underlie MS progression, and for aiding therapeutic decisions.CC BY 4.0, This license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials.http://creativecommons.org/licenses/by/4.0/legalcodeArticle